🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 43% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

2 Softgel(s) Serving Size
30 Servings
Other Combinations Product Type
43% Evidence Coverage

Supplement Facts — Evidence Check

Calories
30 Calorie(s)
Total Fat
3 Gram(s) (2% DV)
Cholesterol
15 mg (5% DV)
Protein
1 Gram(s)
50 mcg (250% DV)
📊 3.3× RDA — above typical dose (UL: 0.1 mg) 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.05mg UL 0.1mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 2100mg UL 3000mg
100 mcg
✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.1mg

Other Ingredients

highly refined and concentrated Omega-3 Fish Oil Gelatin Glycerin Water, Purified D-Limonene Cholecalciferol Vitamin K2 Mixed Tocopherols, Natural

Label Claims — Verification

Nutrient
All Other
Qualified Health
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use: take 2 softgels daily with meal.

⚠️ Warnings & Precautions

Allergen warning: Contains fish and soy derivatives.

Keep out of reach of children.

Do not use if safety seal is damaged or missing.

🧪 Formulation Notes

Omega 2100 mg + K2 & D3 provides a combination of ingredients to support heart and bone health. Vitamin D3 supports your body absorb calcium; and the vitamin K2 transports calcium from the bloodstream into the bone, supporting bone density and cardiovascular health.

Traceability of our Omega-3 oils back to their source.

Purity of our products to safeguard the health of your family. Third party tested

No detectable mercury

Supportive but not conclusive research shows that consumption of EPA and DHA Omega-3 fatty acids may reduce the risk of coronary heart disease.

High-potency Joint & heart support

2,100mg omega-3 1350 mg EPA 600 mg DHA 150 mg DPA + 100 mcg K2 + 2000 IU D3

Additional Information

Ocean blue promise Transparency in our formulations and our labeling. Trust in our stewardship of the Seas.

Manufactured in the USA

(30 day supply)

Friend of the Sea

Great tasting No burps

Store in a cool dry place.

Product Details

UPC / SKU 8 50001 44933 5
DSLD Entry Date 2023-09-25
Product Type Other Combinations
Form Softgel Capsule
DSLD ID 293784
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →